DXCM
DexCom Inc
NASDAQ: DXCM · HEALTHCARE · MEDICAL DEVICES
$84.75
+2.08% today
Updated 2026-08-07
Market cap
$31.49B
P/E ratio
32.98
P/S ratio
6.34x
EPS (TTM)
$2.53
Dividend yield
—
52W range
$54 – $85
Volume
5.2M
WallStSmart proprietary scores
72
out of 100
Grade: B
Buy
Investment rating
8.0
Growth
A7.0
Quality
B+8.5
Profitability
A4.3
Valuation
C5/9
Piotroski F-Score
Moderate
2.7
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →210 stocks currently score above 75
Price targets
Analyst target
$85.33
+0.68%
12-Month target
$63.19
-25.44%
Intrinsic (DCF)
—
Margin of safety
—
3 Strong Buy22 Buy3 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 20.10% — above average
+ ROE 31.47% — strong efficiency
+ Free cash flow $449.00M — positive
+ Revenue growth 13.10% QoQ
+ Debt/equity 0.47x — low leverage
Risks
No major risks identified
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $2.91B | $3.62B | $4.03B | $4.66B | $4.97B | $5.3B |
| Net income | $341.20M | $541.50M | $576.20M | $836.30M | $199.50M | — |
| EPS | — | — | — | — | $2.53 | $2.54 |
| Free cash flow | $304.70M | $511.90M | $630.70M | $1.08B | $449.00M | — |
| Profit margin | 11.73% | 14.95% | 14.29% | 17.94% | 20.10% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-07-20 | SAYER, KEVIN R | Sale | 26,756 | $76.32 |
| 2026-07-15 | BROWN, MICHAEL JON | Sale | 1,700 | $74.42 |
| 2026-07-06 | SAYER, KEVIN R | Sale | 26,756 | $72.00 |
Peer comparison
Smart narrative
DexCom Inc trades at $84.75. representing a P/E of 32.98x trailing earnings. Our Smart Value Score of 72/100 indicates the stock is good. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 2.67, it sits in the grey zone. TTM revenue stands at $4.97B. with profit margins at 20.10%.
Frequently asked questions
What is DexCom Inc's stock price?
DexCom Inc (DXCM) trades at $84.75, on a P/E of 33.0x and a P/S of 6.3x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is DexCom Inc overvalued?
DexCom Inc carries a Smart Value Score of 72/100 (Grade B), which we rate Buy. That score blends growth, quality, and valuation into one read.
What is the price target of DexCom Inc (DXCM)?
The 12-month analyst consensus target is $85.33, about 0.7% above the current $84.75. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of DXCM by 2030?
Our research-backed model puts the 2030 base case at $261.32, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is DexCom Inc's revenue?
DexCom Inc's trailing twelve-month revenue is $4.97B, and our model projects it reaching about $8.52B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
DexCom Inc's Altman Z-Score is 2.67, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio6.34x
ROE31.47%
Beta1.45
50D MA$73.13
200D MA$67.75
Shares out0.38B
Float0.38B
Short ratio—
Avg volume5.2M
Performance
1 week-0.52%
1 month+13.69%
3 months+36.97%
YTD+25.09%
1 year+5.28%
3 years—
5 years—